Repros Therapeutics Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. For the quarter, the company reported total revenues of $547,000 and net loss of $1,347,000 or $0.06 per basic and diluted share against total revenues of $28,000 and net loss of $5,856,000 or $0.39 per basic and diluted share for the same period last year. For the year, the company reported total revenues of $551,000 and net loss of $27,234,000 or $1.57 per basic and diluted share against total revenues of $433,000 and net loss of $25,202,000 or $1.88 per basic and diluted share for the same period last year.

Repros Therapeutics Inc. announced that the company, as requested by the FDA during the Type C meeting held on January 25, 2010, has sent a revised indication statement to the FDA's Division of Reproductive and Urologic Products for the use of Androxal(R) in the treatment of men wishing to preserve fertility while being treated for their hypogonadal state. The Company also provided a literature review supporting the Company's belief that administration of exogenous testosterone at doses resulting in morning testosterone levels within the normal range render a significant number of men oligospermic (sperm counts less than the generally accepted level of male fertility). The Company also submitted the final clinical study report investigating the fertility impact of Androxal compared to a topical testosterone in men previously treated with testosterone for hypogonadism. Previously, the company noted that the FDA suggested it will respond to Repros' submission in a timely fashion following receipt of Repros' materials.

Repros Therapeutics Inc. announced on January 15, 2010 that NASDAQ has granted the Company until May 5, 2010 to meet the continued listing requirements of the NASDAQ Capital Market. Repros began trading on the NASDAQ Capital Market on January 14, 2010. NASDAQ noted the progress made by Repros in resolving creditor debt, as well as the progress the Company has made in executing the plan to regain compliance that was presented to the Appeals Committee in December if the Company was allowed to move to the NASDAQ Capital Markets as part of its decision to allow the Company the additional time. Joseph S. Podolski, President and CEO of Repros, said, We are thankful that NASDAQ has approved our application to move to the NASDAQ Capital Market and granted us the additional time to gain compliance with its listing requirements. The ability to remain a NASDAQ listed Company allows us the greatest flexibility as we consider our financing options going forward. We believe that we will be able to gain compliance with the listing requirements by the May 5, 2010 date. In accordance with the decision of the NASDAQ Hearings Panel, Repros has to meet all of the continued listing requirements of the NASDAQ Capital Market by May 5, 2010, or its securities will, in all likelihood, be delisted from The NASDAQ Stock Market promptly following such date. A Company that has its Primary Equity Security listed on the Capital Market must continue to meet all of the requirements set forth in Rule 5550(a) and at least one of the Standards set forth in Rule 5550(b).

REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and

Repros Therapeutics Inc. Reports Fourth Quarter and Year End 2009 Financial Results

REPROS THERAPEUTICS INC. Files SEC form 10-K, Annual Report

REPROS THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princ

Repros Receives Official FDA Minutes from Type C Androxal® Meeting

REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Repros Receives Official FDA Minutes from Type C Androxal® Meeting

REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Skymark Research Initiates Independent Research Coverage on Repros Therapeutics Inc.

Biopharmaceutical Stock Alert for Repros Therapeutics Inc. Issued by InvestorSoup

Repros Establishes At-the-Market Public Stock Offering Program

REPROS THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh

Skymark Research Initiates Independent Research Coverage on Repros Therapeutics Inc.

Repros Receives Guidance from FDA Regarding Continued Development of Androxal® in Hypogonadal Men

Repros' New IND for the Investigation of Androxal® in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective

Biopharmaceutical Stock Alert for Repros Therapeutics Inc. Issued by InvestorSoup

Repros Establishes At-the-Market Public Stock Offering Program

Repros Submits Response to FDA Regarding Androxal® Indication for Treatment of Hypogonadal Men Wishing to Preserve Fertility

Repros Submits Response to FDA Regarding Androxal® Indication for Treatment of Hypogonadal Men Wishing to Preserve Fertility

Repros Therapeutics gets verbal OK for drug trial